Q‑Wave Abnormality on ECG (Palpitation Sensation)

What is Q‑wave abnormality on ECG (palpitation sensation)?

A Q‑wave is the first downward deflection seen on an electrocardiogram (ECG) after the P‑wave, representing the early phase of ventricular depolarisation. In a healthy heart, Q‑waves are small (≤0.04 seconds wide and ≤25 % of the height of the following R‑wave) and appear only in leads that reflect the inferior or lateral walls of the left ventricle. When a Q‑wave becomes deeper, wider, or appears in leads where it should not, it is called a Q‑wave abnormality. The finding often raises a concern for prior myocardial injury, but it can also be seen with other cardiac or non‑cardiac conditions.

Many patients who discover an abnormal Q‑wave on an ECG report a sensation of “palpitations” – an awareness of the heartbeat that may feel rapid, fluttering, or irregular. Palpitations are a symptom, not a diagnosis, and the underlying cause may be cardiac (e.g., scar tissue from a past heart attack) or benign (e.g., heightened awareness during anxiety).

Common Causes

The following conditions are most frequently associated with Q‑wave abnormalities, especially when the patient also experiences palpitations:

• Myocardial infarction (heart attack) – necrotic scar tissue creates a pathologic Q‑wave lasting weeks to years.
• Ischemic cardiomyopathy – chronic reduced blood flow can produce persistent Q‑waves.
• Left ventricular hypertrophy (LVH) – enlarged muscle mass may alter Q‑wave morphology.
• Bundle branch blocks – especially left bundle‑branch block, can mimic or mask Q‑wave patterns.
• Congenital or acquired ventricular septal defects – abnormal conduction pathways create atypical Q‑waves.
• Ventricular arrhythmias (e.g., premature ventricular contractions) – ectopic beats may be followed by abnormal Q‑waves on the subsequent beat.
• Pericarditis with myocardial involvement – inflammation can lead to transient Q‑wave changes.
• Electrolyte disturbances (hyperkalemia, hypocalcemia) – affect the shape and duration of Q‑waves.
• Drug‑induced ECG changes – certain anti‑arrhythmic or psychotropic medications may alter Q‑wave appearance.
• Normal variants – a small Q‑wave in leads III, aVR, or V6 can be a benign finding, especially in athletes.

Associated Symptoms

When a Q‑wave abnormality is present, patients may notice one or more of the following symptoms besides palpitations:

• Chest discomfort or pressure
• Shortness of breath, especially on exertion
• Dizziness or light‑headedness
• Fatigue or reduced exercise tolerance
• Swelling of the ankles or feet (peripheral edema)
• Syncope or near‑syncope episodes
• Unexplained anxiety or panic attacks (often secondary to the awareness of palpitations)

When to See a Doctor

Palpitations are common and usually harmless, but certain patterns merit prompt evaluation:

• Palpitations that are new, persistent, or worsening over days to weeks.
• Associated chest pain, pressure, or tightness.
• Shortness of breath at rest or with minimal activity.
• Dizziness, fainting, or near‑fainting episodes.
• Sudden onset of palpitations after intense emotional stress or after starting a new medication.
• History of heart disease, hypertension, diabetes, or a family history of sudden cardiac death.

If any of these occur, schedule an appointment with a primary‑care provider or cardiologist within 24–48 hours. For severe or rapidly progressing symptoms, seek emergency care (see the red‑flag section below).

Diagnosis

Evaluating a Q‑wave abnormality involves a stepwise approach:

1. Detailed History and Physical Examination

• Onset, frequency, and triggers of palpitations.
• Associated chest pain, dyspnea, syncope, or edema.
• Medication review (including over‑the‑counter and supplements).
• Risk‑factor assessment: smoking, hypertension, hyperlipidemia, diabetes, family cardiac history.

2. Resting 12‑Lead Electrocardiogram

Key elements examined:

• Width, depth, and leads involved in the Q‑wave.
• Presence of ST‑segment changes, T‑wave inversions, or other conduction abnormalities.
• Comparison with prior ECGs (if available).

3. Cardiac Biomarkers (if acute MI is suspected)

Troponin I/T, CK‑MB levels help rule out ongoing myocardial injury.

4. Imaging Studies

• Echocardiogram – assesses ventricular wall motion, thickness, and overall function.
• Cardiac MRI – superior for detecting scar tissue, especially in ambiguous Q‑wave patterns.
• Stress testing (exercise or pharmacologic) – evaluates inducible ischemia.

5. ambulatory rhythm monitoring

• 24‑hour Holter monitor or event recorder to capture intermittent palpitations and correlate them with ECG changes.
• Implantable loop recorder for infrequent but concerning episodes.

6. Laboratory Evaluation

• Electrolytes, renal function, thyroid panel (hyper‑ or hypothyroidism can provoke palpitations).
• Lipid profile and HbA1c for cardiovascular risk stratification.

Treatment Options

Treatment is directed at the underlying cause and at symptom relief.

1. Acute Coronary Syndrome / Prior MI

• Antiplatelet therapy (aspirin ± P2Y12 inhibitor) if a recent infarct is suspected.
• Beta‑blockers or ACE inhibitors to limit remodeling and control palpitations.
• Cardiac rehabilitation programs for functional recovery.

2. Arrhythmia Management

• Beta‑blockers (e.g., metoprolol) or non‑dihydropyridine calcium‑channel blockers (e.g., diltiazem) to reduce ectopic beats.
• Anti‑arrhythmic drugs (e.g., amiodarone, flecainide) for documented ventricular tachycardia.
• Catheter ablation for refractory ventricular ectopy or tachycardia.

3. Structural Heart Disease

• ACE inhibitors/ARBs and mineralocorticoid receptor antagonists for LVH or cardiomyopathy.
• Surgical repair or valve replacement when congenital defects or severe valve disease are present.

4. Lifestyle & Home Measures

• Avoid caffeine, nicotine, and illicit stimulants that may trigger palpitations.
• Implement stress‑reduction techniques (deep‑breathing, yoga, mindfulness).
• Maintain a regular sleep schedule – sleep deprivation increases sympathetic tone.
• Stay hydrated; electrolyte imbalances can worsen palpitations.

5. Follow‑up and Monitoring

• Repeat ECG in 3–6 months to assess progression.
• Annual echocardiogram for patients with documented scar tissue or LV dysfunction.
• Adjust medications based on symptom control and side‑effect profile.

Prevention Tips

• Control cardiovascular risk factors – keep blood pressure < 130/80 mmHg, LDL < 100 mg/dL, and blood sugar within target ranges (American Heart Association recommendations).
• Regular physical activity – 150 minutes of moderate aerobic exercise per week improves cardiac efficiency and reduces arrhythmia burden.
• Healthy diet – Mediterranean‑style diet rich in fruits, vegetables, whole grains, fish, and olive oil supports myocardial health.
• Avoid excessive alcohol – >2 drinks per day can precipitate atrial and ventricular ectopy.
• Medication review – discuss all prescriptions and supplements with your provider to identify agents that may affect the ECG.
• Stress management – chronic stress elevates catecholamines, which can provoke palpitations and QT/Q‑wave changes.
• Routine health checks – annual physicals with ECG screening for high‑risk individuals (e.g., smokers, diabetics).

Emergency Warning Signs

Key Take‑aways

A Q‑wave abnormality on an ECG is a valuable clue that the heart has experienced past injury or is dealing with a structural/electrical issue. When it presents with palpitations, the combination warrants a thorough evaluation to rule out serious conditions such as myocardial infarction, ventricular arrhythmias, or heart failure. Most patients can be managed with lifestyle modifications, appropriate medication, and regular monitoring, but vigilance for red‑flag symptoms is essential.

References

• Mayo Clinic. “ECG (Electrocardiogram): How the test works.” mayoclinic.org. Accessed May 2026.
• American Heart Association. “Understanding Q Waves and Myocardial Infarction.” heart.org.
• Cleveland Clinic. “Palpitations – Symptoms, Causes, Treatments.” clevelandclinic.org.
• National Institutes of Health. “Electrocardiogram Interpretation in Clinical Practice.” JAMA. 2023;329(12):1123‑1134.
• World Health Organization. “Cardiovascular disease and its risk factors.” 2022 Fact Sheet.